Pharmacyclics Inc $123.06

up +2.82


27/8/2014 04:00 PM  |  NASDAQ : PCYC  
Industries : Drugs / Drug Manufacturers - Other
Get Trend Analysis Icon Get PCYC Trend Analysis - it has underperformed the S&P 500 by 18%

Partner Headlines

  1. Celgene, Gilead Lead Big Biotech Stock Movers

    IBD
  2. Target Expected To Be Right On Target With Earnings

    Benzinga
  3. Pharmacyclics Appoints Chief Commercial Officer

    Benzinga
  4. Pharmacyclics Q2 Earnings Get Mixed Reception

    IBD
  5. Credit Suisse Raises Q2 Imbruvica Sales Forecast For Pharmacyclics

    Benzinga
  6. Pharmacyclics

    IBD
  7. Surges In Biotech Short Interest (INCY, PCYC, RGEN)

    Benzinga
  8. AbbVie Beats Q1 Estimates, Downplays HCV 'Price War'

    IBD
  9. Mid-Afternoon Market Update: Markets Continue to Take a Beating as Rite ...

    Benzinga
  10. Mid-Day Market Update: Rite Aid Shares Gain On Upbeat Earnings; Imperva ...

    Benzinga
  11. Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA with ...

    Benzinga
  12. Morgan Stanley's Top Biotech Pick is Biogen

    Benzinga
  13. Morgan Stanley Starts Pharmacyclics With Equal-Weight; $120 PT -Reuters

    Benzinga
  14. Celegene, Pharmacyclics Lead Biotech Short Interest Trend (CELG, MDVN, ...

    Benzinga
  15. Pharmacyclics target raised

    IBD
  16. Pharmacyclics Drug Imbruvica Beats Rivals: Nomura

    IBD
  17. Kiplinger's Tom Petruno Breaks Down The Best Bull Market Stocks

    Benzinga
  18. WuXi Pharma Q4 Earnings Top, But Q1 Guidance Misses

    IBD
  19. Weekly Insider Sells Highlight: BX, PCYC, MAS, ITMN

    GuruFocus
  20. Pharmacyclics Hits High As Imbruvica Launches Big

    IBD
  21. FDA Approvals And Changes For The Week Ending February 14, 2014

    Benzinga
  22. BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga
  23. Pharmacyclics up on FDA OK

    IBD
  24. Pharmacyclics' Imbruvica Wins Second Cancer Approval

    IBD
  25. Pharmacyclics: Facts Behind $10B Market Cap

    YCharts
  26. $10B Market By 2022: Pharmacyclic’s Piece Of It

    YCharts
  27. ETF Outlook for Wednesday, January 8, 2014 (ROBO, PBE, SMH, EUFN)

    Benzinga
  28. Pharmacyclics, Valeant, Celgene Up On Bullish News

    IBD
  29. Biotechs Jump On Drug News

    IBD
  30. PharmacyclicsDrug Trial To End Early On Strong Data

    IBD
  31. The Top Five Drug Launches Of 2013

    IBD
  32. Rising Short Interest In Pharmacyclics, Other Biotechs (AMGN, GILD, PCYC)

    Benzinga
  33. Qihoo, Noah Lead IBD 50's Top 5 Young Chinese Stocks

    IBD
  34. Pharmacyclics Announces Ibrutinib Frontline Chronic Lymphocytic Leukemia ...

    Benzinga
  35. Celgene, Infinity Rise On Blood Cancer Drug Data

    IBD
  36. 2 Top Biotechs Presenting Data At Hematology Event

    IBD
  37. 4 Potential Blockbuster Drugs Awaiting Launch

    IBD
  38. SouFun, Zeltiq Lead IBD's Top 5 With Bolting RS Lines

    IBD
  39. UPDATE: Piper Jaffray Initiates Coverage on Pharmacyclics as 2014 Biotech ...

    Benzinga
  40. Wedbush Reiterates on Pharmacyclics as IMBRUVICA Approved for Mantle Cell ...

    Benzinga
  41. Market Wrap For November 13: Markets Await Janet Yellen's Big Day Thursday

    Benzinga
  42. Pharmacyclics Drug Wins One Approval, Awaits Another

    IBD
  43. The U.S. Food and Drug Adminstration Approves Pharmacyclis Product For ...

    Benzinga
  44. Pharmacyclics, J&J's Janssen Now Confirming FDA Approval of IMBRUVICA

    Benzinga
  45. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    Benzinga
  46. Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics (BIIB, BMRN, ...

    Benzinga
  47. Pharmacyclics' Ibrutinib Could Crown Turnaround Story

    IBD
  48. J&J Reporting Q3 Earnings As Sentiment Edges Up

    IBD
  49. Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)

    Benzinga
  50. Gilead Stock Jumps On Leukemia Drug News

    IBD
Trading Center